Report of Foreign Issuer (6-k)
August 15 2017 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2017
Commission File Number: 001-37604
OASMIA PHARMACEUTICAL AB
(Name of Registrant)
Vallongatan 1, 752 28 Uppsala, Sweden
(Address of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
OASMIA PHARMACEUTICAL AB
On August 8, 2017, Oasmia Pharmaceutical
AB (“
Oasmia
”) issued a press release (the “
Release
”) announcing that it has received marketing
approval of Doxophos in Russia, a key milestone following the recently established relationship with Hetero Group, Oasmia’s
new marketing and distribution partner. A copy of the Release is attached as an exhibit to this report on Form 6-K. This report
on Form 6-K (including the exhibits hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange
Act of 1934, as amended and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such filing.
Oasmia files reports on Form 6-K with the
US Securities and Exchange Commission (the “
SEC
”) pursuant to the requirements of the Securities Exchange Act
of 1934, as amended. The SEC reports of Oasmia are available to the public over the internet at the SEC’s website at www.sec.gov
and from the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 (telephone 1-800-SEC-0330).
Forward-looking statements
This Form 6-K and the information incorporated
by reference in this Form 6-K include statements that constitute forward-looking statements. In addition, in the future Oasmia
and others on its behalf may make statements that constitute forward-looking statements. When evaluating forward-looking statements,
you should carefully consider the cautionary statement regarding forward-looking information, the risk factors and other information
set forth in Oasmia’s Form F-1 and its reports on Form 6-K furnished to or filed with the SEC, and other uncertainties and
events.
No Offer to Sell Securities
The attached information is not an offer
to sell or a solicitation of an offer to purchase any security in the United States or elsewhere and shall not constitute an offer,
solicitation or sale in any state or jurisdiction in which, or to any person to whom such an offer, solicitation or sale would
be unlawful. No securities may be offered or sold within the United States or to U.S. persons absent registration or an applicable
exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means
of a prospectus that may be obtained from any issuer of such securities and that will contain detailed information about us.
EXHIBITS
Exhibit
Number
|
Description
|
99.1
|
Press Release, dated August 8, 2017, issued by Oasmia Pharmaceutical AB
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
OASMIA PHARMACEUTICAL AB
|
|
|
|
|
Date: August 15, 2017
|
By:
|
/s/ Julian Aleksov
|
|
|
Julian Aleksov
|
|
Executive Chairman
|
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Historical Stock Chart
From Sep 2023 to Sep 2024